BioLife Solutions (BLFS) develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.
Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryo-protectants.
In addition, the company provides custom product formulation and packaging services; contract aseptic manufacturing formulation, fill, and finish services of liquid media products; and precision thermal packaging products and cloud-hosted Web applications.
It markets its products to the regenerative medicine, bio-banking, drug discovery markets, comprising hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets.
BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
April 18, 2019
RegMed Investors’ (RMi) closing bell: sell-off persists with no respect for the sector
April 16, 2019
RegMed Investors’ (RMi) closing bell: the risk-on/risk-off silhouette
April 11, 2019
RegMed Investors’ (RMi) closing bell: more than a few blips, pricing declines outpaced Wednesday’s upside rally ran out of confidence
April 10, 2019
RegMed Investors’ (RMi) closing bell: the unmet needs of share price were lit by low volume momentum for the upsiders
April 9, 2019
RegMed Investors’ (RMi) closing bell: share pricing sustainability was gutted yet again
April 8, 2019
RegMed Investors’ (RMi) closing bell: Q2’s dilemma, regulatory or alliance news doesn’t move the share pricing needle
April 5, 2019
RegMed Investors’ (RMi) closing bell: we are closing the week with a happy ending
April 4, 2019
RegMed Investors’ (RMi) closing bell: another I told you so …
45 companies, 1 interpreter!
Insight, foresight and recommendation
BioLife Solutions (BLFS) – Opened 2018 at $5.96, droppen into February at $5.33, seeing a low of $4.73 yet was trading up at $5.33 on 2/16 after the usual response to news. BLFS on 2/13/18 ... BLFS executed an OEM agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media under private label to MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.